Cargando…

Assessment of ceftolozane/tazobactam degradation profile and toxicity data in elastomeric devices for continuous infusion via outpatient parenteral antimicrobial therapy (OPAT)

Detalles Bibliográficos
Autores principales:	Gilchrist, Mark, Jamieson, Conor, Drummond, Felicity, Hills, Tim, Seaton, R Andrew, Santillo, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108881/ https://www.ncbi.nlm.nih.gov/pubmed/37077650 http://dx.doi.org/10.1093/jacamr/dlad047

Ejemplares similares

Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy
por: Jamieson, Conor, et al.
Publicado: (2021)

P15 Evaluation of the stability of temocillin in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy in accordance with the requirements of the UK NHS Yellow Cover Document
por: Sime, Fekade B., et al.
Publicado: (2022)

Assessment of the stability of citrate-buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements
por: Jamieson, Conor, et al.
Publicado: (2022)

1926. Evaluation of Safety and Effectiveness of Continuous Infusion Ceftolozane/Tazobactam as Outpatient Parenteral Antimicrobial Therapy
por: Jones, Bruce M, et al.
Publicado: (2018)

748 Outpatient Parenteral Antimicrobial Therapy (OPAT) with Continuous Infusions by Elastomeric Infusion Devices in Japan, as an Effective Tool for Better Antimicrobial Stewardship
por: Hase, Ryota, et al.
Publicado: (2014)

Outpatient Parenteral Antimicrobial Therapy With Ceftolozane/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis
por: Álvarez Otero, Judith, et al.
Publicado: (2020)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
por: Terracciano, Joseph, et al.
Publicado: (2017)

Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses
por: Dimitrova, Maria, et al.
Publicado: (2021)

Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
por: Jones, Bruce M, et al.
Publicado: (2020)

Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK
por: Chapman, Ann L N, et al.
Publicado: (2019)

OPAT: outpatient parenteral antimicrobial therapy
Publicado: (2020)

760 Piperacillin/Tazobactam-Induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Yusef, Dawood, et al.
Publicado: (2014)

Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis
por: Duncan, Christopher J. A., et al.
Publicado: (2013)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

Outpatient parenteral antibiotic therapy (OPAT) for the management of bronchiectasis
por: Tu, Jacky, et al.
Publicado: (2023)

Stability of Ampicillin plus Ceftriaxone Combined in Elastomeric Infusion Devices for Outpatient Parenteral Antimicrobial Therapy
por: Fernández-Rubio, Beatriz, et al.
Publicado: (2023)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
por: Pedersen, Maya Graham, et al.
Publicado: (2015)

Outpatient parenteral antimicrobial therapy (OPAT) in a safety-net hospital: Opportunities for improvement
por: Bouzigard, Rory, et al.
Publicado: (2023)

Being ‘at-home’ on outpatient parenteral antimicrobial therapy (OPAT): a qualitative study of parents’ experiences of paediatric OPAT
por: Carter, Bernie, et al.
Publicado: (2020)

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting
por: Venuti, Francesco, et al.
Publicado: (2023)

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
por: Van Anglen, Lucinda J, et al.
Publicado: (2017)

A broader view on outpatient parenteral antibiotic therapy (OPAT) stewardship
por: Hess, Danielle, et al.
Publicado: (2022)

Effectiveness of outpatient parenteral antimicrobial therapy (OPAT) for patients with cranial infection
por: Kilinc, Fatma, et al.
Publicado: (2023)

353. Outpatient parenteral antimicrobial therapy (OPAT) in managing vertebral osteomyelitis
por: Villacorta Cari, Evelyn, et al.
Publicado: (2023)

Ampicillin Stability in a Portable Elastomeric Infusion Pump: A Step Forward in Outpatient Parenteral Antimicrobial Therapy
por: Rodríguez-Martínez, Lorena, et al.
Publicado: (2023)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

1923. OPAT or No-PAT? Evaluation of Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Daptomycin or Ertapenem for “Ease of Administration”
por: Britt, Rachel S, et al.
Publicado: (2018)

1854. Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers
por: Nathan, Ramesh V, et al.
Publicado: (2018)

345. Unaccounted Costs Associated with Different Outpatient Parenteral Antimicrobial Therapy (OPAT) Models of Care
por: Player, Jacob, et al.
Publicado: (2023)

Follow-up Appointment Adherence of Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients
por: Lall, Ambika, et al.
Publicado: (2017)

1855. Antimicrobial Stewardship (AMS) and the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting
por: Friedman, N Deborah
Publicado: (2018)

777. Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Burnett, Yvonne, et al.
Publicado: (2019)

623. Self-Administered Outpatient Parenteral Antimicrobial Therapy (S-OPAT) in Uninsured Patients
por: Hamad, Yasir, et al.
Publicado: (2020)

Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
por: Ferreiro, Jose Luis Lamas, et al.
Publicado: (2021)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Nathan, Ramesh V, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qaqinnv29gmu965et200ee4ei0